Quarterly report [Sections 13 or 15(d)]

Stockholders’ Deficit (Details Narrative)

v3.26.1
Stockholders’ Deficit (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
May 26, 2026
Mar. 31, 2026
Dec. 15, 2025
Sep. 29, 2025
Jul. 02, 2025
Nov. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Oct. 16, 2025
Oct. 15, 2025
Nov. 02, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Capital stock par value                           $ 0.001
Common stock, shares authorized             1,000,000,000   1,000,000,000   1,000,000,000 1,000,000,000 100,000,000 100,000,000
Preferred stock, shares authorized             5,000,000   5,000,000   5,000,000     5,000,000
Redeemable common stock     $ 1,228           $ 1,228      
Redemption value $ 963                   1,228      
Right to appoint board of directors description                 Pursuant to the Membership Interest Purchase Agreement, so long as DNA Holdings, directly or indirectly, beneficially owns at least 5% of the Company’s outstanding common stock, DNA Holdings will have the right under the Membership Interest Purchase Agreement to designate one officer and one nominee for election to the Company’s board of directors, and the Company will be required to take reasonably necessary corporate action to appoint such designees, subject to the oversight of the Company’s nominating and governance committee. DNA Holdings designated Scott Walker for appointment to the Company’s Board of Directors and on January 30, 2026 the Board of Directors appointed Scott Walker to service on the Board as a director.          
Investment in DNA X, LLC $ 1,290               $ 1,242      
Other income expense             48        
Stock price $ 4.315                          
Charged to accumulated deficit $ 63 $ (328)           879 $ 63 1,215        
Stock issued during period, value               5,415   8,952        
Common stock par value             $ 0.001   $ 0.001   $ 0.001      
DNA Holdings Ventures Inc.                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Convertble notes issued     $ 1,200                      
Membership interest description     The Membership Interest Purchase Agreement also grants DNA Holdings a put option (the “Put Option”). If at any time prior to June 30, 2026 (the “Put Period”) DNA X does not realize either (i) aggregate trading volume of at least $600,000,000 or (ii) aggregate revenues of at least $1,000,000 per day, DNA Holdings will have the right, during the Put Period, to exchange the shares of common stock issued to DNA Holdings under the Membership Interest Purchase Agreement for the Purchased Interests then held by the Company. To the extent not exercised during the Put Period, the Put Option will terminate upon the expiration of the Put Period. See below for discussion of termination of the Put Option on May 26, 2026.                      
Common stock                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock price $ 4.315                          
Charged to accumulated deficit                        
Stock issued during period, value               $ 4   $ 5        
Stock issued during period, shares [1]               179,657   254,516        
Common stock | ChEF Purchase Agreement                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock issued during period, value       $ 500,000   $ 79                
Common stock par value       $ 0.001                    
Stock issued during period, shares           12,300                
Placement Agent Warrants                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Warrants purchase for common stock         11,604                  
Warrants exercise price per share         $ 13.50                  
Warrants         Jul. 02, 2030                  
Warrants adjustment description         The exercise prices of the Placement Agent Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, stock combinations, reorganizations or similar events affecting the Common Stock. Subject to limited exceptions, a holder of Placement Agent Warrants will not have the right to exercise any portion of its Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any Warrants, 9.99%) of the shares of common stock then outstanding. At the holder’s option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding.                  
Membership Interest Purchase Agreement | Common stock                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares issued on acquisitions     223,201                      
Redeemable common stock     $ 1,228                      
DNA X LLC                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Membership interests     100.00%                      
DNA Holdings Ventures Inc.                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Membership interests     19.99%                      
[1] Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1.